Categories
Change Password!
Reset Password!
DMab can help to check both, systemic and articular bone loss
in RA patients along with minimum adverse effects.
Rheumatoid arthritis (RA) is a
chronic inflammatory diseases marked by focal pathologic bone resorption. This
is due to the excessive activity of osteoclasts (OC). The receptor activator of
nuclear factor kappa B ligand (RANKL) is significant for the proliferation,
differentiation, and survival of OC. Denosumab (DMab) is a humanized monoclonal
antibody. It binds to RANKL with high affinity and blocks its subsequent
alliance with its receptor RANK on the surface of OC precursors.
The authors of this study review
the molecular and cellular mechanisms underlying therapeutic applications of
DMab, supplement recent highlights on pharmacology, efficacy and safety of
DMab, and discuss the potential of DMab as a novel therapeutic option for the
rheumatoid arthritis treatment.
Thus, the clinical results revealed
that DMab is efficient both in systemic and articular bone loss in RA with
finite side effects. The RA patients on corticosteroids and bisphosphonates
displayed diminished bone erosion activity. The blend of DMab with an anti-TNF
agent was not connected with increased infection rates.
All in all, the data obtained from
this study point-out that DMab, in combination with methotrexate and possibly
other conventional synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs),
is an effective, safe and cost-effective choice for the treatment of RA.
Expert Opin Biol Ther.
Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis
Yahui Grace Chiu, Christopher T. Ritchlin
Comments (0)